Media stories about Minerva Neurosciences (NASDAQ:NERV) have trended somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Minerva Neurosciences earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.727734305682 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news stories that may have effected Accern Sentiment’s analysis:
- Minerva Neurosciences Names Dr. Justine Lalonde as Senior Vice President, Product Strategy – GlobeNewswire (press release) (globenewswire.com)
- Golf Equipment Market Size to Grow at a Steady Rate During Forecast Period 2016 – 2022 (reports.pr-inside.com)
- Minerva Neurosciences to Report Third Quarter 2017 Financial Results and Business Updates on November 6 … – Markets Insider (markets.businessinsider.com)
- Minerva Neurosciences to Report Third Quarter 2017 Financial Results and Business Updates on November 6, 2017 (finance.yahoo.com)
Shares of Minerva Neurosciences (NASDAQ NERV) traded down $0.25 during midday trading on Monday, reaching $5.75. 128,495 shares of the company’s stock were exchanged, compared to its average volume of 111,030. Minerva Neurosciences has a twelve month low of $5.55 and a twelve month high of $14.15. The company has a current ratio of 5.35, a quick ratio of 5.35 and a debt-to-equity ratio of 0.01.
Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.28) EPS for the quarter. During the same quarter last year, the company posted ($0.24) EPS. sell-side analysts predict that Minerva Neurosciences will post -1.26 EPS for the current fiscal year.
Several research firms have commented on NERV. BidaskClub downgraded shares of Minerva Neurosciences from a “hold” rating to a “sell” rating in a report on Monday, July 24th. Zacks Investment Research downgraded shares of Minerva Neurosciences from a “buy” rating to a “hold” rating in a report on Thursday, October 5th. Finally, Citigroup Inc. began coverage on shares of Minerva Neurosciences in a report on Friday, September 1st. They set a “buy” rating and a $11.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $13.94.
WARNING: This piece of content was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/11/06/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-minerva-neurosciences-nerv-share-price.html.
About Minerva Neurosciences
Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.
What are top analysts saying about Minerva Neurosciences Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Minerva Neurosciences Inc and related companies.